DAZD
An independent third-party medical diagnostic service institution with the diagnostic service outsourcing as its core business
DAZD, founded in September, 2001 and headquartered in Hangzhou, is an independent third-party medical diagnostic service organization. The founder is Chen Haibin. Listed on the SZSE on July 19, 2011, the company's major shareholders are Chen Haibin, Hong Kong Securities Clearing Co., Ltd and China Huarong Asset Management Co., Ltd. Rivals that have direct and indirect competition with DAZD include KingMed, Genomics, Progyny, BioNTech SE, etc.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
East China medicine "liraglutide" goes to sea
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Hungry? The drug purchase service has covered 93% of the urban area of Shanghai, with a cumulative distribution of more than 2.2 million orders
Huitian new material has recently conducted several rounds of price adjustment for products in major application industries